chronic HCV infection

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Baseline insulin resistance (HOMA-IR >2) was independently associated with failure to achieve sustained virological response during pegIFN-α-2a and ribavirin retreatment of HIV/HCV co-infected patient

Effect: decline; AOR 0.17; CI: 95% CI 0.05–0.64

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)

Retreatment with pegIFN-α-2a and weight-based ribavirin achieved sustained virological response in 15% of HIV/HCV co-infected patients who had previously failed interferon-based therapy.

Effect: improvement; 15% SVR (14/96)